PFE logo

PFE
Pfizer Inc

105,814
Mkt Cap
$247.53B
Volume
11.96M
52W High
$27.69
52W Low
$20.92
PE Ratio
15.03
PFE Fundamentals
Price
$25.90
Prev Close
$25.78
Open
$25.83
50D MA
$25.20
Beta
0.42
Avg. Volume
92.65M
EPS (Annual)
$1.41
P/B
1.58
Rev/Employee
$785,518.52
Loading...
Loading...
News
all
press releases
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
Zacks·1h ago
News Placeholder
More News
News Placeholder
Guru Fundamental Report for PFE
Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy of...
Nasdaq News: Markets·3h ago
News Placeholder
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
Zacks·4h ago
News Placeholder
Pfizer Inc. $PFE Shares Sold by Becker Capital Management Inc.
Becker Capital Management Inc. lowered its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 58.4% in the second quarter, according to the company in its most recent filing with the...
MarketBeat·8h ago
News Placeholder
Pfizer (NYSE:PFE) Trading Up 1.7% - Here's Why
Pfizer (NYSE:PFE) Trading Up 1.7% - Here's Why...
MarketBeat·17h ago
News Placeholder
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.
Zacks·19h ago
News Placeholder
Pharmaceutical Stocks To Follow Today - December 10th
Eli Lilly and Company, AbbVie, Pfizer, Novo Nordisk A/S, and Terns Pharmaceuticals are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical...
MarketBeat·23h ago
News Placeholder
PFE Factor-Based Stock Analysis
Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy of...
Nasdaq News: Markets·1d ago
News Placeholder
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA (tucatinib) as part of an investigational first-line maintenance...
Business Wire·1d ago
News Placeholder
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
Zacks·1d ago

Latest PFE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.